Insmed
CompanyUnited States
Insmed develops 2 assets, the furthest approved (Brinuspry in non-cystic fibrosis bronchiectasis). Mostly small molecule acting on inflammation, CTSC and PTGIR; based in the United States.
- 2
- Assets
- Furthest stage
- Approved
- 3
- Trials
- 0
- Signals
Pipeline
2Inhibits dipeptidyl peptidase 1, reducing activation of neutrophil serine proteases and associated inflammation.
Approved, Small molecule, Inflammation, CTSC, non-cystic fibrosis bronchiectasis
Prodrug of treprostinil that activates prostacyclin receptors to dilate pulmonary vessels.
Phase 3, Small molecule, PTGIR, interstitial lung disease, pulmonary arterial hypertension
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- Signals3
- Similar companies6